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We present what is to our knowledge a 
rare presentation of colistin-induced angio-
oedema.[1]
Case report
A 50-year-old woman presented to Tygerberg 
Hospital, Cape Town, South Africa (SA), 
with dysuria, and suprapubic and lower 
abdominal pain. She was known to have had 
type 1 diabetes mellitus for 24 years and had 
microvascular complications in the form of 
retinopathy (with blindness of the right eye), 
neuropathy and nephropathy. Her estimated 
glomerular filtration rate had declined from 
a baseline of 31 mL/min/1.73 m2 2 months 
earlier to 18 mL/min/1.73 m2 at presentation. 
She was admitted with sepsis due to a 
complicated urinary tract infection and her 
urine cultured Acinetobacter baumannii, 
sensitive only to colistin. She was initiated 
on intravenous colistin, dose adjusted for her 
degree of renal impairment. Five hours after 
the infusion, she developed urticaria and 
angio-oedema involving the face, lips and 
tongue, but with no laryngeal involvement or 
anaphylaxis. She had no personal or family 
history of angio-oedema or of any other 
allergy or atopy. She was not known to have 
had prior exposure to colistin. At the time of 
angio-oedema diagnosis, she had received 
subcutaneous insulin (24 years), enalapril 
(5  years), amlodipine (5 years), simvastatin 
(5  years), aspirin (5 years), furosemide 
(1 year) and colistin (5 hours) (Fig. 1).
The patient was successfully managed 
with prompt discontinuation of the colistin 
infusion, administration of promethazine, 
hydro cortisone, oxygen via facemask and 
supportive care, with provision for escala-
tion of care if symptoms worsened. There 
was no indication for intubation, and the 
angio-oedema resolved over 72 hours. Her 
A. baumannii urosepsis was successfully 
treated with intravenous tigecycline and oral 
rifampicin.
Angiotensin-converting enzyme inhibitor 
(ACE-I) angio-oedema was considered,[2-5] as 
ACE-I angio-oedema may develop months 
or even years after commencing therapy.[2,4,6] 
However, she improved and had complete 
resolution of symptoms despite continu-
ing with enalapril. While other concomitant 
medications (insulin, amlodipine, furose-
mide, simvastatin) could theoretically cause 
angio-oedema, it is highly unlikely because 
of their continued use.
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A 50-year-old woman known to have type 1 diabetes mellitus presented with a rare case of angio-oedema associated with colistin use. The 
angio-oedema was temporally associated with the use and discontinuation of colistin with the reasonable exclusion of important differential 
diagnoses. Pseudoallergy may be a probable underlying mechanism. However, we cannot exclude the possibility of hereditary angio-oedema 
type 2 or 3, or that her concomitant medications (particularly enalapril) and her renal impairment contributed to the risk and severity of 
her angio-oedema.
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Fig. 1. Causality assessment.
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Hereditary angio-oedema (HAE) type 1 or 2 is unlikely because of the 
absence of a family history and the first occurrence in the patient’s 
6th decade.[4,7] HAE-1 was excluded with a normal C4  level of 
0.23 g/L (normal range 0.20 - 1.00) and a slightly elevated C1 esterase 
inhibitor (C1-INH) level of 0.49 g/L (0.21 - 0.40). The normal 
C4 level makes HAE-2 unlikely, but a definite diagnosis requires 
evaluation of the function of C1-INH, which is not readily available 
in SA. The elevated C1-INH level observed in our patient may have 
been due to the underlying sepsis. HAE-3, which is more common 
in females and at an older age, remains a possibility, but F-12 gene 
mutation testing is unavailable in SA.
Acquired angio-oedema, also known as acquired C1-INH defi-
ciency, is due to autoantibodies against C1-INH as a result of 
autoimmune or lymphoproliferative diseases.[3,8] This was considered 
because our patient had type 1 diabetes mellitus and was therefore 
at risk of other autoimmune diseases. However, she had a normal 
C3 level of 1.05 g/L (0.50 - 1.53).
The temporal association between the administration of colistin and 
development of symptoms that resolved with the prompt discontinuation 
of colistin makes the diagnosis of colistin-induced angio-oedema likely. 
Rechallenge with colistin would have confirmed our diagnosis but 
was considered inappropriate. Pseudoallergy may be the most likely 
mechanism for our patient’s colistin-induced angio-oedema. This is a 
result of the offending agent binding directly to mast cells and inducing 
their degranulation with release of inflammatory mediators, particularly 
histamine,[3] leading to angio-oedema and urticaria.[9] It does not require 
IgE mediation[3,10] and no prior sensitisation is needed.
Conclusion
We present what is to our knowledge a rare case of colistin-
induced angio-oedema temporally associated with the use and 
discontinuation of colistin with the reasonable exclusion of important 
differential diagnoses. However, we cannot exclude the possibility 
that her concomitant medication (particularly enalapril) and her 
renal impairment contributed to the risk and severity of her angio-
oedema.
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